Literature DB >> 10191298

Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins.

H E Henderson1, J J Kastelein, A H Zwinderman, E Gagné, J W Jukema, P W Reymer, B E Groenemeyer, K I Lie, A V Bruschke, M R Hayden, H Jansen.   

Abstract

Lipoprotein lipase (LPL) is crucial in the hydrolysis of triglycerides (TG) in TG-rich lipoproteins in the formation of HDL particles. As both these lipoproteins play an important role in the pathogenesis of atherosclerotic vascular disease, we sought to assess the relationship between post-heparin LPL (PH-LPL) activity and lipids and lipoproteins in a large, well-defined cohort of Dutch males with coronary artery disease (CAD). These subjects were drawn from the REGRESS study, totaled 730 in number and were evaluated against 75 healthy, normolipidemic male controls. Fasting mean PH-LPL activity in the CAD subjects was 108 46 mU/ml, compared to 138 44 mU/ml in controls (P < 0.0001). When these patients were divided into activity quartiles, those in the lowest versus the highest quartile had higher levels of TG (P < 0.001), VLDLc and VLDL-TG (P = 0.001). Conversely, levels of TC, LDL, and HDLc were lower in these patients (P = 0.001, P = 0.02, and P = 0.001, respectively). Also, in this cohort PH-LPL relationships with lipids and lipoproteins were not altered by apoE genotypes. The frequency of common mutations in the LPL gene associated with partial LPL deficiency (N291S and D9N carriers) in the lowest quartile for LPL activity was more than double the frequency in the highest quartile (12.0% vs. 5.0%; P = 0.006). By contrast, the frequency of the S447X LPL variant rose from 11.5% in the lowest to 18.3% (P = 0.006) in the highest quartile. This study, in a large cohort of CAD patients, has shown that PH-LPL activity is decreased (22%; P = 0.001) when compared to controls; that the D9N and N291S, and S447X LPL variants are genetic determinants, respectively, in CAD patients of low and high LPL PH-LPL activities; and that PH-LPL activity is strongly associated with changes in lipids and lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10191298

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  20 in total

1.  A new monoclonal antibody, 4-1a, that binds to the amino terminus of human lipoprotein lipase.

Authors:  André Bensadoun; Charlene D Mottler; Chris Pelletier; Daniel Wu; Jane J Seo; Calvin S Leung; Oludotun Adeyo; Chris N Goulbourne; Peter Gin; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  Biochim Biophys Acta       Date:  2014-03-28

2.  Genetic Determinants of Dyslipidemia in African-Based Populations: A Systematic Review.

Authors:  Jean Jacques Noubiap; Edith Pascale M Mato; Magellan Guewo-Fokeng; Arnaud D Kaze; Houssam Boulenouar; Ambroise Wonkam
Journal:  OMICS       Date:  2018-12

3.  The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease.

Authors:  Mehmet Agirbasli; Mutlu Cagan Sumerkan; Fatih Eren; Deniz Agirbasli
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

4.  Associations of genetic variants for adult lipid levels with lipid levels in children. The Generation R Study.

Authors:  Ardashel Latsuzbaia; Vincent W V Jaddoe; Albert Hofman; Oscar H Franco; Janine F Felix
Journal:  J Lipid Res       Date:  2016-10-24       Impact factor: 5.922

5.  Lipoprotein lipase gene sequencing and plasma lipid profile.

Authors:  Dilek Pirim; Xingbin Wang; Zaheda H Radwan; Vipavee Niemsiri; John E Hokanson; Richard F Hamman; M Michael Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Lipid Res       Date:  2013-11-09       Impact factor: 5.922

6.  Increased postprandial triglyceride-rich lipoprotein levels in elderly survivors of myocardial infarction.

Authors:  Samira Lekhal; Trond Børvik; Arne Nordøy; John-Bjarne Hansen
Journal:  Lipids       Date:  2008-04-04       Impact factor: 1.880

7.  Molecular genetics of myocardial infarction.

Authors:  Yoshiji Yamada; Sahoko Ichihara; Tamotsu Nishida
Journal:  Genomic Med       Date:  2008-08-14

Review 8.  Pharmacogenetics of glucose-lowering drug treatment: a systematic review.

Authors:  Ozlem Bozkurt; Anthonius de Boer; Diederick E Grobbee; Eibert R Heerdink; Huib Burger; Olaf H Klungel
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity.

Authors:  Lionel Bey; Marc T Hamilton
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

10.  Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia.

Authors:  Katherine K Anagnostopoulou; Genovefa D Kolovou; Peggy M Kostakou; Constantinos Mihas; Georgios Hatzigeorgiou; Christina Marvaki; Dimitrios Degiannis; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Lipids Health Dis       Date:  2009-06-26       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.